Author: Kathleen Musson

Oklahoma Society of Clinical Oncology, Inc.
Presents
2018 Oklahoma Society of Clinical Oncology (OSCO) Update from Spring/Summer Oncology Meetings
Earn up to 3.75 AMA PRA Category 1 Credits™
Saturday, September 15, 2018
8:00 a.m.—12:15 p.m.
OU Andrews Academic Tower
Stanton L. Young Blvd.
Oklahoma City, OK
1st Floor —Conference Rooms A, B, and C
Register Online: OUHSC.CLOUD-CME.Com

Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Oklahoma College of Medicine and the Oklahoma Society of Clinical Oncology, Inc. The University of Oklahoma College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Oklahoma College of Medicine designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Conflict Resolution Statement:
The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity’s speaker and planner disclosures and resolved all identified conflicts of interest, if applicable.
Activity Description:
T2018 Oklahoma Society of Clinical Oncology (OSCO) Update from Spring/Summer Oncology Meetings will highlight the foremost research and strategies in oncology that were presented at the 2018 ASCO® Annual Meeting. Topics will include Neo and Post-op Adjuvant Therapy in Pancreatic Cancer, Advances in Combination Immunotherapies for Melanoma, Results of TAILORx (Trial Assigning Individualized Options for Treatment) and Advances in Lung Cancer.
Intended/Target Audience:
Hematologists and Oncologists, Nurses, Pharmacists, Physician Assistants and other health care professionals specializing in Oncology.
Overall Learning Objectives:
Upon completion of this activity, participants will improve their competence and performance by being able to:
1. Discuss the latest advances in combination immunotherapies for Melanoma.
2. Explain the TAILORx Results (Trial Assigning Individualized Options for Treatment).
Discuss FOLFIRINOX – Neo and Post-op Adjuvant Therapy in Pancreatic Cancer.
Identify the latest advances in lung cancer treatment.
Planning Committee Members:
William C. Dooley, MD, FACS, Course Director
Jose Eugenio Najera, MD
Mary K. Lindemuth, MD, PGY-4, Surgery Resident
Kathy Musson - Course Contact
Doctors Dooley and Lindemuth will share moderator responsibilities throughout the course.

Nondiscrimination Statement:
The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices or procedures. This includes, but is not limited to: admissions, employment, financial aid and educational services. Inquiries regarding non-discrimination policies may be directed to: Bobby J. Mason, Institutional Equity Officer, (405) 325-3546, bjm@ou.edu, or visit www.ou.edu/eoo.
Accommodation Statement:
Accommodations on the basis of disability are available by contacting Kathy Musson by phone at (405) 850-8334 or by e-mail to kmussonokc@gmail.com as soon as possible.
Acknowledgement of Commercial and In-Kind Support:
Commercial support is financial, or in-kind, contributions given by a commercial interest, which is used to pay all or part of the costs of a CME activity. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
Appropriate acknowledgement of all commercial and in-kind support will be given at the time of the educational activity.
Disclaimer Statement:
Statements, opinions and results of studies contained in the program are those of the presenters, authors and joint provider and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.
Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.
Policy on Faculty, Joint Provider and Presenters Disclosure:
It is the policy of the University of Oklahoma, College of Medicine that the faculty, presenters and joint provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s).
Further Information is available by contacting Kathy Musson, Executive Director of the Oklahoma Society of Clinical Oncology, Inc. by e-mail at kmussonokc@gmail.com or by phone at (405) 850-8334.
Accreditation Council for Graduate Medical Education (ACGME):
American Board of Medical Specialties (ABMS) Competencies:
Patient Care
Medical Knowledge

Registration Fee:
Register at https://ouhsc.cloud-cme.com/aph.aspx
Registration Fee: Physicians—$75 Other Health Care Professionals—$25
Registration for this year’s conference will be online through the OU College of Medicine, Office of Continuing Professional Development website. Please visit the website for instructions on how to sign in and register for the conference.
Parking information for attendees of the 2018 Oklahoma Society of Clinical Oncology (OSCO) Update from Spring/Summer Oncology Meetings . Andrews Academic Tower Conference Center, Entrance off Stanton L. Young Blvd
Visitor/Events Parking available in Lot 11F. Gate code available upon request.
OUHSC residents and staff are to park in their normal parking areas.
Speaker Information

2018 Oklahoma Society of Clinical Oncology (OSCO) Update from Spring/Summer Oncology Meetings
CME # 19007
September 15, 2018
Andrews Academic Tower 1st Floor Conference Rooms A, B, and C
OU Health Sciences Center
First Name: Middle Last Name
Degree Specialty
Address
City State Zip
Phone (____) Fax (____) Cell Phone (Required)
Date of Birth NPI Number
Emergency Contact Name Phone (____)
Please provide an email address that you will be able to access. You will use this address to complete your evaluation and print your CME certificate.
*Email
*Please indicate whether you consent to the receipt of future promotional electronic messages from the University of Oklahoma, College of Medicine Office of Continuing Professional Development by marking the box in the affirmative and by executing where noted below and providing us with your email address. We will not share your email or contact information with anyone outside of the CPD office.
□ I consent to the receipt of future promotional electronic messages from the University of Oklahoma, College of Medicine, Office of CPD
□ I decline to receive future promotional electronic messages from the University of Oklahoma, College of Medicine Office of CPD
Registration Type (please select one)
TOTAL AMOUNT DUE: $_______________
Payment Method:
I Departmental Transfer (OUHSC only) Chartfield spread: MISCA COM015 00014 00000
P Purchase order (please e-mail a copy of the PO to jan-quayle@ouhsc.edu)
I Check: Check Number:____________
I Credit Card: (Visa, MasterCard, or Discover)
Card Number __________________________Expiration Date __________________Total Amount Charged $______________
Signature_________________________________ Name as it appears on card (please print) _____________________________
MAIL WITH PAYMENT TO:
OUHSC, Office of CPD
PO Box 26901, AAT 4000
Oklahoma City, OK 73126-0901
Tax ID: #73-156-3627
For questions or more information, contact Susie Dealy: susie-dealy@ouhsc.edu or 405-271-2350, ext. 1

Geoffrey T. Gibney, MD
Co-Leader Melanoma Disease Group at Lombardi Comprehensive Cancer Center and Medstar Georgetown University Hospital

Stephanie Graff, MD,
Sarah Cannon Cancer Institute
HCA Midwest Health

Nagla Abdel Karim, MD, PhD
Professor of Medicine, Augusta University/Medical College of Georgia

Hedy Lee Kindler, MD, FASCO
Professor of Medicine, University of Chicago Medicine
Oncology/Research - Geisinger Health System

Oklahoma Society of Clinical Oncology, Inc.
Presents the
2018 Oklahoma Society of Clinical Oncology (OSCO) Update from Spring/Summer Oncology Meetings
Saturday, September 15, 2018
Andrews Academic Tower
800 Stanton L. Young Blvd.
Oklahoma City, Oklahoma 73104
Conference Rooms A, B, and C
Moderators: William C. Dooley, MD, FACS and Mary K. Lindemuth, MD, PGY-4, Surgery Resident
7:00 am Exhibitor Setup
7:15–8:00 am Registration & Continental Breakfast
8:00–8:15 am Introductions/Announcements
8:15–8:55 am We’re FINALLY Making Progress in Pancreatic Cancer: Updates from ASCO®
Hedy Lee Kindler, MD, FASCO
University of Chicago Medicine
8:55–9:05 am Q&A
9:05–9:45 am Combination Immunotherapy Strategies in Melanoma and Other Malignancies -
Current State and Future Directions
Geoffrey T. Gibney, MD
Georgetown University
9:45–9:55 am Q&A
9:55–10:15 am Break for exhibits/refreshments
10:15–10:55 am TAILORx and the Modern Landscape of Gene Expression in Early Stage Breast Cancer
Stephanie Graff, MD
Sarah Cannon Cancer Institute HCA Midwest Health
10:55–11:05 am Q&A
11:05–11:45 am Advances in Lung Cancer—Emerging Treatment Options
Nagla Abdel Karim, MD, PhD
Augusta University/Medical College of Georgia
11:45 am–12:15 pm Questions & Answers with Whole Panel
12:15 pm Adjourn

Oklahoma Society of Clinical Oncology, Inc.
The Oklahoma Society of Clinical Oncology, Inc. (OSCO) serves as the hub for oncology-related news and advances in Oklahoma. Our organization is made up of clinics and healthcare professionals working together to safeguard the rights of patients and to maintain high medical and ethical standards in the industry.
OSCO Charter
Advance the sciences of hematology and oncology and its sub-specialties and improve services to the public by studying the socio-economic aspects of the practice of its members.
Encourage improved educational opportunities for members.
Promote interchange between members.
Safeguard the rights of patients with neoplastic diseases.
Define the qualifications of physicians practicing hematology and oncology in Oklahoma.
Serve as spokesperson and liaison to governmental and insurance interests on behalf of its members.
Disseminate information regarding legislative and regulatory developments affecting the issues of common concern to members.
Promote scientific inquiry and exchange between members.
Establish and maintain high medical and ethical standards for members.
Promote good fellowship among its members.
OSCO Board of Directors
2018-2019

Eugenio Najera, MD, President
Cancer Centers of Southwest Oklahoma
Samuel Bieligk, MD, FACS, Treasurer
Saint Francis Health System
William C. Dooley, MD, FACS, Past-President
OU Medical Center, Dept of Surgery
Raid Aljumaily, MD, Board Member
Stephenson Cancer Center
Todd M. Kliewer, MD, Board Member
SSM Health-Saint Anthony Hospital
George Selby, MD, Board Member
Stephenson Cancer Center

Christina E. Henson, MD, Board Member
Stephenson Cancer Center
Jordan Morton, MD, Board Member
Mercy Clinic Oncology & Hematology
Sanjay Patel, MD, Board Member
Stephenson Cancer Center
Susanna Ulahannan, MD, Board Member
Stephenson Cancer Center
Kathy Musson, CAE, Executive Director
Oklahoma Society of Clinical Oncology, Inc.
P.O. Box 720024
Oklahoma City, OK 73172
Office: 405-850-8334
kmussonokc@gmail.com
www.OKclinicaltrials.org
www.OSCOok.org

	Registration Type	Registration Rate
	Physicians	$75
	Other Healthcare Providers	$25
	Residents/Students	No Charge (call 405-271-2350 for online registration instructions)